Article Text

Download PDFPDF
Systematic review
Cochrane Review highlights the need for more targeted research on the tolerability of malaria chemoprophylaxis in travellers
  1. Patricia Schlagenhauf
  1. Dr Patricia Schlagenhauf
    University of Zürich Centre for Travel Medicine, WHO Collaborating Centre for Travellers’ Health, Hirschengraben 84, CH8001 Zürich, Switzerland; pat{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on:

The recent Cochrane Collaboration review by Jacquerioz and Croft on drugs to prevent malaria in travellers is a welcome evaluation of randomised controlled trials of malaria chemoprophylaxis in non-immune individuals. The goal of the systematic review was to evaluate the efficacy, safety and tolerability of atovaquoneproguanil, doxycycline and mefloquine (the three priority regimens for malaria prophylaxis) compared with each other, with the defunct combination chloroquineproguanil and with primaquine (considered in some countries to be a candidate for chemoprophylaxis of travellers’ malaria).

This systematic review is particularly valuable for the fact that the stringent selection process meant that only scientifically rigorous trials were included. The authors used appropriate search terms and strategies in screening the chosen databases (the Cochrane Infectious Diseases Group Specialised Register, the Cochrane Central …

View Full Text


  • Competing interests PS has received research grants, consultancy fees and speaker’s honoraria from GlaxoSmithKline and F. Hoffmann-La Roche